5-phenyl-pyrimidine derivatives

US6756380B1 · kind B1 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Michael Bos · Montréal, CA
• Guido Galley · Rheinfelden (Baden), DE
• Thierry Godel · Basel, CH
• Torsten Hoffmann · Weil am Rhein, DE
• Walter Hunkeler · Magden, CH
• Patrick Schnider · Bottmingen, CH
• Heinz Stadler · Basel, CH

Key dates

• Filing date: May 22, 2000
• Grant date: Jun 29, 2004
• Expiry date: May 22, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/48
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the general formula are described: whereinR1 is hydrogen or halogen;R2 is hydrogen, halogen, lower alkyl or lower alkoxy;R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl;R4/R4′are each independently hydrogen or lower alkyl;R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, —(CH2)n-piperazinyl, optionally substituted by lower alkyl, —(CH2)n-morpholinyl, —(CH2)n+1-imidazolyl, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n—NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl;R6 is hydrogen;R2 and R6 or R1 and R6 may together be —CH═CH—CH═CH—, wherein R2 and R6 or R1 and R6, respectively, together with the two carbon ring atoms to which they are attached form a fused ring, with the proviso that n for R1 is 1;n is independently 0-2; andX is —C(O)N(R4″)— or —N(R4″)C(O)—;and pharmaceutically acceptable acid addition salts ther…